Thyrocare Technologies Limited — Investor Meet, 14-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Thyrocare posted strong Q4 FY'26 consolidated revenue of INR 224 Cr (+20% YoY) and full-year revenue of INR 829 Cr (+21% YoY). Profit after tax surged 128% YoY in Q4 to INR 48.7 Cr. Gross margins expanded to 74.7%, with EBITDA margins at 34%. Operational highlights include 10,800 active franchisees and 210 million tests processed in FY'26. Management is strategically expanding into specialty diagnostics like genomics and allergy testing, aiming for 15-20% of test mix in three years. They anticipate mid-to-high teens revenue growth for FY'27, driven mostly by volume, with stable EBITDA margins. A new brand for allied diagnostic consumables is also planned. Focus remains on affordable, high-quality testing.